Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL547150 | 0.98 | AR (0.62) | ARNR3C1 | |
| SCHEMBL19880022 | 0.90 | AR (0.51) | AR | |
| SCHEMBL2990385 | 0.89 | AR (0.61) | ARNR3C1 | |
| SCHEMBL3661137 | 0.88 | AR (0.60) | ARNR3C1 | |
| SCHEMBL21155640 | 0.88 | AR (0.51) | ARNR3C1 | |
| SCHEMBL3919465 | 0.88 | AR (0.64) | ARNR3C1 | |
| SCHEMBL29508770 | 0.87 | AR (0.65) | ARNR3C1 | |
| SCHEMBL30184879 | 0.87 | AR (0.75) | ARNR3C1 | |
| SCHEMBL547047 | 0.87 | AR (0.75) | ARNR3C1 | |
| SCHEMBL547406 | 0.87 | AR (0.65) | ARNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210069154-A1 | Treatment of Breast Cancer | MEDIVATION PROSTATE THERAPEUTICS LLC | 2021-03-11 | — | — | US | disclosed |
| US-20190262315-A1 | Treatment of Breast Cancer | MEDIVATION PROSTATE THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
| US-9896437-B2 | Diarylhydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-02-20 | — | — | US | disclosed |
| US-9896437-B2 | Diarylhydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-02-20 | — | — | US | disclosed |
| US-20170087132-A1 | Treatment of Breast Cancer | MEDIVATION PROSTATE THERAPEUTICS LLC | 2017-03-30 | — | — | US | disclosed |
| US-9517229-B2 | Treatment of breast cancer | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20150065546-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065546-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-05 | — | — | US | disclosed |
| EP-2397469-B1 | Diarylhydantoin compounds | UNIV CALIFORNIA (US) | 2014-12-31 | — | — | EP | disclosed |
| US-20140296312-A1 | TREATMENT OF BREAST CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2014-10-02 | — | — | US | disclosed |
| US-8680291-B2 | Diarylhydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680291-B2 | Diarylhydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-03-25 | — | — | US | disclosed |
| EP-2620432-A2 | Diarylhydantoin compounds | The Regents Of the University of California (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2397469-A1 | Diarylhydantoin compounds | The Regents Of the University of California (US) | 2011-12-21 | — | — | EP | disclosed |
| EP-2397469-A1 | Diarylhydantoin compounds | The Regents Of the University of California (US) | 2011-12-21 | — | — | EP | disclosed |
| EP-2220050-A2 | DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | The Regents Of The University Of California (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20090111864-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-30 | — | — | US | disclosed |
| WO-2009055053-A2 | DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009055053-A2 | DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065546-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, ACP3, AR | AR 3/4885NR3C1 682/4885 |
| US-20190262315-A1 | Treatment of Breast Cancer | BRCA1, TP53, TUBB6 | AR 2403/4885NR3C1 2943/4885 |
| US-20170087132-A1 | Treatment of Breast Cancer | BRCA1, MKI67, BAX | AR 2292/4885NR3C1 4330/4885 |
| US-20140296312-A1 | TREATMENT OF BREAST CANCER | BRCA1, BAX, BAD | AR 2166/4885NR3C1 4290/4885 |
| US-20090111864-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, ACP3, AR | AR 3/4885NR3C1 682/4885 |
| US-20210069154-A1 | Treatment of Breast Cancer | BRCA1, TP53, TUBB6 | AR 2403/4885NR3C1 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.